Case Report: Unilateral relapsing primary central nervous system vasculitis-expanding the phenotype., PMID:40529356
Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma., PMID:40528731
Treatment Options for the Comorbidity of Multiple Sclerosis With Other Chronic Inflammatory Diseases., PMID:40526577
The anti-CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B-cell lymphomas., PMID:40524014
A Phase 2 Study of Obinutuzumab Combined with Lenalidomide in Previously Untreated High Tumor Burden Follicular Lymphoma., PMID:40517417
Evaluating the Role of CAR-T Cell Therapy in the Context of Current Therapy Options for Patients With Relapsed or Refractory Follicular Lymphoma., PMID:40516919
Beyond BCL2 (B cell lymphoma) and BTK (Bruton tyrosine kinase) inhibitors: novel agents and resistance mechanisms for chronic lymphocytic leukemia., PMID:40515863
Native structure of the monoclonal therapeutic CD20 antibody ocrelizumab., PMID:40513927
Pharmacokinetics, Receptor Occupancy, and Pharmacodynamics of Obexelimab Following Intravenous Administration in Adult Healthy Volunteers and in Patients With Rheumatoid Arthritis., PMID:40512061
Role of Ocrelizumab in modulating gene and microRNA expression in multiple sclerosis., PMID:40510879
QSP modeling of loncastuximab tesirine with T-cell-dependent bispecific antibodies guides dose-regimen strategy., PMID:40500294
Factors for Rituximab Refractoriness in AQP4-IgG+ NMOSD: A Cohort Study., PMID:40492601
Potential use of the SARS-CoV-2 monoclonal antibody sipavibart in people with multiple sclerosis: definition of different patient archetypes from an Italian expert group perspective., PMID:40481170
Haemophagocytic lymphohistiocytosis (HLH) secondary to measles in an adult with a loss of post-vaccination humoral immunity following rituximab., PMID:40480240
Uveal melanoma following Bruton's tyrosine inhibitor use for the treatment of hematologic malignancies., PMID:40475129
The Role of Novel Immunomodulators in the Treatment of Autoimmune Hepatitis., PMID:40474885
Utilization of anti-CD20 antibodies for treatment of childhood nephrotic syndrome, 2010 to 2022., PMID:40473981
Advances in the treatment of ANCA-associated vasculitis., PMID:40473820
CD20×CD3 Bispecific Antibodies in B-NHL: A Review of Translational Science, Pharmacokinetics, Pharmacodynamics, and Dose Strategy in Clinical Research., PMID:40471801
CONFIDENCE treatment success: long-term real-world effectiveness and safety of ocrelizumab in Germany., PMID:40470489
Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)., PMID:40468805
[Severe late-onset neutropenia after rituximab administration]., PMID:40467890
Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma., PMID:40467383
Targeting B Cells and Plasma Cells in Glomerular Disease., PMID:40465397
Oral lichen planus in a patient treated with anti-CD20 monoclonal antibodies., PMID:40465334
Predictive factors and nomogram for the risk of cytokine release syndrome with anti-CD3 × CD20 bispecific antibodies for Chinese patients., PMID:40464994
Pathogenesis, Diagnosis, Treatment, and Prognosis of CD20-Positive T and NK Cell Lymphoma: A Review., PMID:40460386
Hitting the Therapeutic Bullseye with Targeted Therapy for Patients with Chronic Lymphocytic Leukemia., PMID:40456120
Recent advances in monoclonal antibody development for treatment of B-cell acute lymphoblastic leukemia., PMID:40455243
Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched study., PMID:40451284
Rituximab Use for Relapse Prevention in Anti-NMDAR Antibody-Mediated Encephalitis: A Multicenter Cohort Study., PMID:40446185
Rituximab for a rare pediatric case of concurrent thyroid eye disease and myasthenia gravis., PMID:40443484
Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study., PMID:40442445
Ocrelizumab-Induced Hemophagocytic Lymphohistiocytosis: A Case Report., PMID:40438805
Use of rituximab in connective tissue disease-associated interstitial lung disease: a narrative review., PMID:40438359
Efficacy and safety of epcoritamab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma: 3-year follow-up from the EPCORE NHL-3 trial., PMID:40434509
Vaccine-Induced Humoral and Cellular Response to SARS-CoV-2 in Multiple Sclerosis Patients on Ocrelizumab., PMID:40432100
COVID-19 Vaccination in Patients with Hematological Malignances., PMID:40432077
Dysregulated Adaptive Immune Responses to SARS-CoV-2 in Immunocompromised Individuals., PMID:40431250
Unsupervised Clustering of Cell Populations in Germinal Centers Using Multiplexed Immunofluorescence., PMID:40427719
Single-Agent and Associated Therapies with Monoclonal Antibodies: What About Follicular Lymphoma?, PMID:40427101
The Prognostic Impact of the Tumor Immune Microenvironment in Synovial Sarcoma: An Immunohistochemical Analysis Using Digital Pathology and Conventional Interpretation., PMID:40423041
Obinutuzumab-Induced Inflammatory Bowel Disease-Like Colitis., PMID:40421460
Severe Hypokalemic Paralysis Following Rituximab Infusion in a Patient With Microscopic Polyangitis., PMID:40416913
Antibody polymer drug conjugates with increased drug to antibody ratio: CD38-targeting nanomedicines for innovative therapy of relapsed lymphomas., PMID:40409372
Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis., PMID:40402264
Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders., PMID:40402079
CXCL13 and CCL21 Induce Tertiary Lymphoid Structures and Enhance the Efficacy of Immunotherapy for Melanoma., PMID:40393449
Additive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy., PMID:40388905
Rituximab treatment in non-lupus full-house nephropathy: A case report., PMID:40371307
For research use only. Not for human or drug use.
